430 related articles for article (PubMed ID: 37490245)
1. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
2. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
Park KW
Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
[TBL] [Abstract][Full Text] [Related]
3. Passive Immunotherapies Targeting Amyloid-
Marković M; Milošević J; Wang W; Cao Y
Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
[TBL] [Abstract][Full Text] [Related]
4. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
5. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
8. Vascular Considerations for Amyloid Immunotherapy.
Foley KE; Wilcock DM
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):709-719. PubMed ID: 36269539
[TBL] [Abstract][Full Text] [Related]
9. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
10. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
Fedele E
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
[TBL] [Abstract][Full Text] [Related]
11. Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
[TBL] [Abstract][Full Text] [Related]
12. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
Cummings J; Osse AML; Cammann D; Powell J; Chen J
BioDrugs; 2024 Jan; 38(1):5-22. PubMed ID: 37955845
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
15. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
17. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
18. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
19. More failure with solanezumab - this time in preclinical Alzheimer's disease.
Doggrell SA
Expert Opin Biol Ther; 2024 Mar; 24(3):119-123. PubMed ID: 38414336
[TBL] [Abstract][Full Text] [Related]
20. Lessons from antiamyloid-β immunotherapies in Alzheimer's disease.
Plascencia-Villa G; Perry G
Handb Clin Neurol; 2023; 193():267-292. PubMed ID: 36803816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
